Pfizer, Novartis: CDC’s MenB nod is too narrow

Carly Helfand Pfizer and Novartis have snagged a nod from the CDC's Advisory Committee on Immunization Practices (ACIP) for their recently approved meningitis B vaccines. ...

Novartis looks to squelch neuro worries over its would-be cardio blockbuster

Damian Garde Novartis, at work on a cardio drug widely expected to bring in billions of dollars once approved, is working to tamp down concerns that the oral treatment could increase ...

U.K. readies dementia R&D investment fund

Nick Paul Taylor Few could fault the United Kingdom for aiming too low. Having seen its CNS R&D chops whittled away by Big Pharma cuts, the U.K. government has decided the best ...

Dr. Reddy’s drug prices in crosshairs of two states

Eric Palmer Generic Dr. Reddy's Laboratories, which already has had to defend its drug pricing to a couple of members of Congress, is now being called to account by the attorneys ...

Deal-weighing Pharmacyclics could draw $18B from J&J, Novartis: Bloomberg

Carly Helfand So far, the 2014 pharma deal blitz has continued right on into 2015. And cancer drugmaker Pharmacyclics could be the next company to keep it going. FiercePharma News

Introducing FierceBiotech’s new podcast

Damian Garde Welcome to FierceBiotech Radio, a podcast in which we'll chat with industry experts, newsmakers and veterans on issues affecting the business of biopharma. The idea ...

Exclusive: Pfizer is once again cutting back R&D staff in reorganization

John Carroll Pfizer is once again trimming its R&D staff. Responding to a query from FierceBiotech regarding word of cutbacks at research facilities in Cambridge, MA, and Collegeville, ...

Consumer group petitions FDA to pull generic antifungal med

Carly Helfand Currently, there are several generics on the U.S. market of oral antifungal agent ketoconazole. But consumer advocacy organization Public Citizen is trying to change that. FiercePharma ...

Cebix hangs it up after raising $50M for diabetes drug

Damian Garde La Jolla, CA's Cebix has quietly closed up shop, Xconomy reports, after its once-promising diabetes candidate failed to hit the mark in Phase IIb. FierceBiotech News

Takeda makes an M&A move in Turkey

Eric Palmer Takeda's CEO-in-waiting, Christophe Weber, has included emerging markets, along with oncology and gastrointestinal medicines, as one of three areas of focus. He recently ...

PTC is trawling for a buyer with its risky DMD drug, Reuters says

Damian Garde PTC Therapeutics is looking to get bought, Reuters' sources say, betting that a larger company will covet its treatment for Duchenne muscular dystrophy enough to overlook ...

Novartis bags a surprise approval for the blood cancer-treating panobinostat

Damian Garde Going against the advice of its independent experts, the FDA approved Novartis' new blood cancer drug for patients with particularly deadly forms of multiple myeloma, ...
Page 1 of 912345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS